{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T05:24:14Z","timestamp":1782019454629,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271735"],"award-info":[{"award-number":["82271735"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejpn.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:31:53Z","timestamp":1759541513000},"page":"38-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Value of creatine kinase and creatinine as biomarkers in nusinersen-treated children with spinal muscular atrophy"],"prefix":"10.1016","volume":"59","author":[{"given":"Jielu","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6736-1407","authenticated-orcid":false,"given":"Shanshan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejpn.2025.10.001_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"15","key":"10.1016\/j.ejpn.2025.10.001_bib2","article-title":"Spinal muscular atrophy: the past, present, and future of diagnosis and treatment","volume":"24","author":"Nishio","year":"2023","journal-title":"Int. J. Math. Stat."},{"issue":"11","key":"10.1016\/j.ejpn.2025.10.001_bib3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1212\/WNL.0000000000201654","article-title":"Prevalence of spinal muscular atrophy in the era of disease-modifying therapies","volume":"100","author":"Coratti","year":"2023","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ejpn.2025.10.001_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1474-4422(23)00419-2","article-title":"Challenges and opportunities in spinal muscular atrophy therapeutics","volume":"23","author":"Yeo","year":"2024","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.ejpn.2025.10.001_bib5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile\u2010onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2025.10.001_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13023-017-0724-z","article-title":"Indirect estimation of the prevalence of spinal muscular atrophy type I, II, and III in the United States","volume":"12","author":"Lally","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"issue":"10","key":"10.1016\/j.ejpn.2025.10.001_bib7","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14737175.2017.1364159","article-title":"Nusinersen for the treatment of spinal muscular atrophy","volume":"17","author":"Chiriboga","year":"2017","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.ejpn.2025.10.001_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","article-title":"Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy","volume":"17","author":"Pera","year":"2017","journal-title":"BMC Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2025.10.001_bib9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul. Disord."},{"issue":"6","key":"10.1016\/j.ejpn.2025.10.001_bib10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"},{"issue":"9","key":"10.1016\/j.ejpn.2025.10.001_bib11","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41591-024-03142-z","article-title":"Proteomic signatures improve risk prediction for common and rare diseases","volume":"30","author":"Carrasco-Zanini","year":"2024","journal-title":"Nat. Med."},{"issue":"7846","key":"10.1016\/j.ejpn.2025.10.001_bib12","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41586-021-03221-y","article-title":"Creatine kinase B controls futile creatine cycling in thermogenic fat","volume":"590","author":"Rahbani","year":"2021","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ejpn.2025.10.001_bib13","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/ene.12995","article-title":"Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis","volume":"23","author":"Rafiq","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.ejpn.2025.10.001_bib14","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.clinph.2018.01.071","article-title":"Creatine kinase level and its relationship with quantitative electromyographic characteristics in amyotrophic lateral sclerosis","volume":"129","author":"Tai","year":"2018","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.ejpn.2025.10.001_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2019.10.025","article-title":"Creatinine: from physiology to clinical application","volume":"72","author":"Kashani","year":"2020","journal-title":"Eur. J. Intern. Med."},{"issue":"4","key":"10.1016\/j.ejpn.2025.10.001_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000469669","article-title":"Serum creatinine: not So simple","volume":"136","author":"Delanaye","year":"2017","journal-title":"Nephron"},{"issue":"5","key":"10.1016\/j.ejpn.2025.10.001_bib17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/acn3.51340","article-title":"Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment","volume":"8","author":"Freigang","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.ejpn.2025.10.001_bib18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s13023-024-03515-0","article-title":"A cross-sectional and longitudinal evaluation of serum creatinine as a biomarker in spinal muscular atrophy","volume":"19","author":"Zhao","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejpn.2025.10.001_bib19","article-title":"Association among biomarkers, phenotypes, and motor milestones in Chinese patients with 5q spinal muscular atrophy types 1\u20133","volume":"15","author":"Ouyang","year":"2024","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.ejpn.2025.10.001_bib20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3233\/JND-230054","article-title":"Identifying biomarkers of spinal muscular atrophy for further development","volume":"10","author":"Glascock","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"issue":"7","key":"10.1016\/j.ejpn.2025.10.001_bib21","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1515\/cclm-2023-1311","article-title":"Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges","volume":"62","author":"Bayoumy","year":"2024","journal-title":"Clin. Chem. Lab. Med."},{"issue":"10","key":"10.1016\/j.ejpn.2025.10.001_bib22","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1515\/cclm-2022-0637","article-title":"Plasma neurofilament light chain in Chinese children with later-onset spinal muscular atrophy","volume":"60","author":"Jin","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.ejpn.2025.10.001_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/11772719211035643","article-title":"Update on biomarkers in spinal muscular atrophy","volume":"16","author":"Pino","year":"2021","journal-title":"Biomark. Insights"},{"issue":"7","key":"10.1016\/j.ejpn.2025.10.001_bib24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/acn3.324","article-title":"Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy","volume":"3","author":"Hijikata","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"1\u20132","key":"10.1016\/j.ejpn.2025.10.001_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jns.2007.08.012","article-title":"Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females","volume":"264","author":"Sorar\u00f9","year":"2008","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.ejpn.2025.10.001_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1515\/cclm-2018-0656","article-title":"Diagnostic biomarkers of muscle injury and exertional rhabdomyolysis","volume":"57","author":"Lippi","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"issue":"9","key":"10.1016\/j.ejpn.2025.10.001_bib27","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008762","article-title":"Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy","volume":"94","author":"Alves","year":"2020","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.ejpn.2025.10.001_bib28","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ejpn.2025.10.001_bib29","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.nmd.2021.03.012","article-title":"Age related treatment effect in type II Spinal Muscular atrophy pediatric patients treated with nusinersen","volume":"31","author":"Coratti","year":"2021","journal-title":"Neuromuscul. Disord."},{"issue":"8","key":"10.1016\/j.ejpn.2025.10.001_bib30","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s12519-025-00938-y","article-title":"Sustainable efficacy of nusinersen in children with later-onset spinal muscular atrophy: a 3-year observational study","volume":"21","author":"Feng","year":"2025","journal-title":"World J Pediatr"},{"issue":"8","key":"10.1016\/j.ejpn.2025.10.001_bib31","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/acn3.51411","article-title":"Nusinersen in pediatric and adult patients with type III spinal muscular atrophy","volume":"8","author":"Pera","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.ejpn.2025.10.001_bib32","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s13023-022-02547-8","article-title":"Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study","volume":"17","author":"Pechmann","year":"2022","journal-title":"Orphanet J. Rare Dis."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379825001515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379825001515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:51:06Z","timestamp":1773154266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379825001515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":32,"alternative-id":["S1090379825001515"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2025.10.001","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Value of creatine kinase and creatinine as biomarkers in nusinersen-treated children with spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}